PBMI Webinar – Diabetes: Multifaceted Approaches to Address Adherence, Cost, and Improved Outcomes
Diabetes is the leading cost driver for WellDyneRx clients, accounting for more than 10% of total drug expenditures, and these numbers are continuing to rise as the epidemic spreads. As the most expensive therapeutic class in terms of traditional drug spend, diabetes medications cost more than specialty medications for oncology, multiple sclerosis, and HIV. Additionally, medication adherence rates for diabetes therapy tend to be poor, and overall hemoglobin A1c levels do not appear to be trending downward despite increases in associated drug treatment costs.
Presented by PBMI and WellDyneRx, this complimentary webinar session will review new ways to improve delivery of care to patients with diabetes.
Tuesday, April 17, 2018 @ 1:30 – 2:30 pm ET.
Register today at: https://register.gotowebinar.com/register/962353439051073025